1. 1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. (September 2015) Authors: Lüftner, D.; Grischke, E.M.; Fasching, P.; Decker, T.; Schneeweiss, A.; Uleer, C.; Foerster, F.; Wimberger, P.; Kluth-Pepper, B.; Schubert, J.; Bloch, W.; Tesch, H.; Schuetz, F.; Jackisch, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S288 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. (June 2019) Authors: Mavratzas, A.; Baek, S.; Gerber, B.; Schmidt, M.; Moebus, V.; Foerster, F.; Grischke, E.M.; Fasching, P.; Strumberg, D.; Solomayer, E.; Klare, P.; Windemuth-Kieselbach, C.; Hartmann, S.; Schneeweiss, A.; Marmé, F. Journal: Breast Issue: Volume 45(2019) Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1805 Association between HER2-phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer. (September 2015) Authors: Janni, W.; Schramm, A.; Friedl, T.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P.; Taran, F.A.; Hartkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Pantel, K.; Krawczyk, N.; Fehm, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i. (December 2018) Authors: Lanzinger, S.; Schmid, S.M.; Welp, R.; Zimmermann, A.; Fasching, P.; Wagner, S.; Holl, R.W. Journal: Diabetes research and clinical practice Issue: Volume 146(2018) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2. (November 2022) Authors: Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V.K.; Biswas, C.; Haftchenary, S.; Pathak, P.; Rugo, H. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. (April 2023) Authors: Kümmel, S.; Schmid, P.; Harbeck, N.; Takahashi, M.; Untch, M.; Boileau, J.-F.; Cortes, J.; McArthur, H.; Dent, R.; O'Shaughnessy, J.; Pusztai, L.; Foukakis, T.; Park, Y.H.; Hui, R.; Cardoso, F.; Denkert, C.; Zhu, Y.; Pan, W.; Karantza, V.; Fasching, P. Journal: Breast Issue: Volume 68(2023)Supplement Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗